---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-25-000024"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T11:02:09.152950+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience FY2024 net loss $61.4M; cash $169M; two directors departing

## Summary
- Net loss $61.4M for FY2024 vs $36.3M in 2023; R&D expense $47M, G&A $21.6M.
- Cash and equivalents $169M as of Dec 31, 2024; expected to fund operations into 2028.
- Directors Jeff Chen and Maha Radhakrishnan will not stand for re-election at 2025 annual meeting; board size to shrink from 7 to 5.
- ALTO-300 Phase 2b MDD trial interim analysis positive; topline results expected mid-2026.
- ALTO-203 Phase 2 MDD trial enrollment complete; topline data expected Q2 2025.

## SEC filing metadata
- accession: 0001999480-25-000024
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/alto-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-25-000024
- JSON: https://secwatch.observer/filing/0001999480-25-000024.json
- Plain text: https://secwatch.observer/filing/0001999480-25-000024.txt

## Key facts
- Executive change
  Maha Radhakrishnan departed as Director at Alto Neuroscience, Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: Also on March 17, 2025, Maha Radhakrishnan, M.D. informed the Company's board of directors (the "Board") that she will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm
- Executive change
  Jeff (Po Yu) Chen departed as Director at Alto Neuroscience, Inc..
  - Action: will not stand for re-election
  - Role: Director
  source text: On March 17, 2025, Jeff (Po Yu) Chen, Ph.D. informed the Company's board of directors (the "Board") that he will not stand for re-election as a Class I director at the Company's 2025 Annual Meeting of Stockholders.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948025000024/0001999480-25-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.